CN108348509A - 用于治疗增殖减少性病症的化合物 - Google Patents

用于治疗增殖减少性病症的化合物 Download PDF

Info

Publication number
CN108348509A
CN108348509A CN201680063630.0A CN201680063630A CN108348509A CN 108348509 A CN108348509 A CN 108348509A CN 201680063630 A CN201680063630 A CN 201680063630A CN 108348509 A CN108348509 A CN 108348509A
Authority
CN
China
Prior art keywords
alkyl
group
compound
substituent group
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063630.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·弗吕加勒
L·约翰逊
T·伦德贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lu Licensing Co
Original Assignee
Lu Licensing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lu Licensing Co filed Critical Lu Licensing Co
Publication of CN108348509A publication Critical patent/CN108348509A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
CN201680063630.0A 2015-11-03 2016-11-03 用于治疗增殖减少性病症的化合物 Pending CN108348509A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1551419-3 2015-11-03
SE1551419 2015-11-03
PCT/EP2016/076550 WO2017076968A1 (en) 2015-11-03 2016-11-03 Compounds for treatment of hypoproliferative disorders

Publications (1)

Publication Number Publication Date
CN108348509A true CN108348509A (zh) 2018-07-31

Family

ID=57326350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063630.0A Pending CN108348509A (zh) 2015-11-03 2016-11-03 用于治疗增殖减少性病症的化合物

Country Status (11)

Country Link
US (1) US11471446B2 (pt)
EP (1) EP3370720A1 (pt)
JP (1) JP6977238B2 (pt)
KR (1) KR20180073600A (pt)
CN (1) CN108348509A (pt)
AU (1) AU2016348659B2 (pt)
BR (1) BR112018008931A8 (pt)
CA (1) CA3002495A1 (pt)
IL (1) IL258593B (pt)
MX (1) MX2018005158A (pt)
WO (1) WO2017076968A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
AU2020216498A1 (en) 2019-02-01 2021-09-23 Senex Biotechnology, Inc Bicyclic pyridine compositions and methods of using the same for cancer therapy
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
GB202208226D0 (en) * 2022-06-06 2022-07-20 Royal Veterinary College Method and treatment for osteoarthritis and diseases of chondrocyte hypertrophy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649581A (zh) * 2002-06-06 2005-08-03 贝林格尔.英格海姆药物公司 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
WO2013138101A2 (en) * 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN104363913A (zh) * 2012-02-02 2015-02-18 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CN104903321A (zh) * 2012-11-08 2015-09-09 赛尔维他股份公司 作为激酶抑制剂的经取代三环苯并咪唑
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219234A1 (en) 2004-04-12 2007-09-20 Kiyoshi Oizumi Thienopyridine Derivatives
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EA027531B1 (ru) * 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
MX2015002310A (es) 2012-08-23 2015-06-05 Hoffmann La Roche Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
EP2928893A1 (en) 2012-12-10 2015-10-14 F. Hoffmann-La Roche AG Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194201A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649581A (zh) * 2002-06-06 2005-08-03 贝林格尔.英格海姆药物公司 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
CN104363913A (zh) * 2012-02-02 2015-02-18 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
WO2013138101A2 (en) * 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN104903321A (zh) * 2012-11-08 2015-09-09 赛尔维他股份公司 作为激酶抑制剂的经取代三环苯并咪唑
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHENG WEI ET AL.: "Lenalidomide Promotes p53 Degradation by Inhibiting MDM2 Auto-ubiquitination in Myelodysplastic Syndrome with Chromosome 5q Deletion", 《ONCOGENE》 *
STEFANO FUMAGALLI ET AL.: "The Role of p53 in Ribosomopathies", 《SEMINARS IN HEMATOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US11471446B2 (en) 2022-10-18
BR112018008931A2 (pt) 2018-11-06
IL258593A (en) 2018-06-28
IL258593B (en) 2021-04-29
KR20180073600A (ko) 2018-07-02
EP3370720A1 (en) 2018-09-12
AU2016348659B2 (en) 2022-07-28
CA3002495A1 (en) 2017-05-11
WO2017076968A1 (en) 2017-05-11
JP2018532784A (ja) 2018-11-08
US20190111034A1 (en) 2019-04-18
JP6977238B2 (ja) 2021-12-08
AU2016348659A1 (en) 2018-05-31
BR112018008931A8 (pt) 2019-02-26
MX2018005158A (es) 2019-05-16

Similar Documents

Publication Publication Date Title
CN108348509A (zh) 用于治疗增殖减少性病症的化合物
JP5393489B2 (ja) 蛋白キナーゼの阻害剤として有用なアミノピリミジン
Er et al. Novel substituted benzothiazole and Imidazo [2, 1-b][1, 3, 4] Thiadiazole derivatives: Synthesis, characterization, molecular docking study, and investigation of their in vitro antileishmanial and antibacterial activities
CN104066431B (zh) 吡嗪激酶抑制剂
EP2262498A2 (en) Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2010497A1 (en) Compositions and methods for modulating gated ion channels
JP2017538676A (ja) ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
WO2008046072A2 (en) Chemical inducers of neurogenesis
CZ290474B6 (cs) Isoxazol-4-karboxamidy, způsob jejich výroby, farmaceutický prostředek tyto sloučeniny obsahující a jejich pouľití
EP2311809A1 (en) Quinolinyloxyphenylsulfonamides
JP7109919B2 (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN106132934A (zh) 治疗炎性病症的苯并咪唑衍生物及其医药组合物
JP2015500844A (ja) トリヘテロ環式誘導体、調製方法及びそれらの使用
WO2019173613A1 (en) Substituted fused pyrrolo-diazepinones and uses thereof
JP2009543874A (ja) チアゾリジノン誘導体
UA62015C2 (en) Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
RU2749038C2 (ru) Замещенные пирроло[2,3-d]пиридазин-4-оны и пиразоло[3,4-d]пиридазин-4-оны в качестве ингибиторов протеинкиназы
CN110317173A (zh) 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
JP6768662B2 (ja) Ｎａｄｐｈオキシダーゼに関連する状態の処置に使用するための化合物
JP6879557B2 (ja) インフラマソームを標的とする低分子化合物
CN104602681A (zh) 取代的吡啶酰胺激酶抑制剂
JP2008528552A (ja) 新規のインドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
KR101861869B1 (ko) 신규한 비스-아미드 유도체 및 이의 용도
WO2018096525A2 (en) Heteroaryl compounds and uses thereof
US11952328B2 (en) Selective ship inhibitors for treating disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731